Cargando…
Atopic Dermatitis in Older Adults: A Review of Treatment Options
Atopic dermatitis (AD) in older adults (elderly AD) has recently emerged as a newly defined subgroup of AD. When selecting treatment options, clinical characteristics of elderly AD and age-specific factors of older patients must be considered. As in other age groups, regular application of moisturiz...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044141/ https://www.ncbi.nlm.nih.gov/pubmed/32086792 http://dx.doi.org/10.1007/s40266-020-00750-5 |
_version_ | 1783501503354372096 |
---|---|
author | Tanei, Ryoji |
author_facet | Tanei, Ryoji |
author_sort | Tanei, Ryoji |
collection | PubMed |
description | Atopic dermatitis (AD) in older adults (elderly AD) has recently emerged as a newly defined subgroup of AD. When selecting treatment options, clinical characteristics of elderly AD and age-specific factors of older patients must be considered. As in other age groups, regular application of moisturizers in combination with topical corticosteroids and calcineurin inhibitors, adjunctive administration of oral antihistamines/anti-allergic drugs, and avoidance of exacerbating factors comprise basic treatments for elderly AD. For moderate-to-severe cases and/or in those with a decreased ability to use topical treatments, powerful anti-inflammatory treatments may become necessary as additional treatment options. While low-dose oral corticosteroids may be useful for cases of elderly AD, careful attention should be paid to adverse effects. Oral cyclosporine (ciclosporin) is less commonly used due to the increased risk of malignancy and organ toxicity in older patients with AD. Narrow-band ultraviolet B phototherapy may also be useful for older patients, although the necessity of frequent hospital visits for irradiation therapy may become a burden of disease for such patients. As a biologic, dupilumab therapy markedly improves skin lesions and itch in older patients with AD, with a rapid response and non-serious adverse effects. Nevertheless, injection pain, expensive medical care, and regular follow-up every 2 weeks are disadvantages of dupilumab therapy. Therefore, clinicians must prioritize individualized treatment options that will reduce the burden of disease for cases of elderly AD. |
format | Online Article Text |
id | pubmed-7044141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-70441412020-03-10 Atopic Dermatitis in Older Adults: A Review of Treatment Options Tanei, Ryoji Drugs Aging Review Article Atopic dermatitis (AD) in older adults (elderly AD) has recently emerged as a newly defined subgroup of AD. When selecting treatment options, clinical characteristics of elderly AD and age-specific factors of older patients must be considered. As in other age groups, regular application of moisturizers in combination with topical corticosteroids and calcineurin inhibitors, adjunctive administration of oral antihistamines/anti-allergic drugs, and avoidance of exacerbating factors comprise basic treatments for elderly AD. For moderate-to-severe cases and/or in those with a decreased ability to use topical treatments, powerful anti-inflammatory treatments may become necessary as additional treatment options. While low-dose oral corticosteroids may be useful for cases of elderly AD, careful attention should be paid to adverse effects. Oral cyclosporine (ciclosporin) is less commonly used due to the increased risk of malignancy and organ toxicity in older patients with AD. Narrow-band ultraviolet B phototherapy may also be useful for older patients, although the necessity of frequent hospital visits for irradiation therapy may become a burden of disease for such patients. As a biologic, dupilumab therapy markedly improves skin lesions and itch in older patients with AD, with a rapid response and non-serious adverse effects. Nevertheless, injection pain, expensive medical care, and regular follow-up every 2 weeks are disadvantages of dupilumab therapy. Therefore, clinicians must prioritize individualized treatment options that will reduce the burden of disease for cases of elderly AD. Springer International Publishing 2020-02-21 2020 /pmc/articles/PMC7044141/ /pubmed/32086792 http://dx.doi.org/10.1007/s40266-020-00750-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Article Tanei, Ryoji Atopic Dermatitis in Older Adults: A Review of Treatment Options |
title | Atopic Dermatitis in Older Adults: A Review of Treatment Options |
title_full | Atopic Dermatitis in Older Adults: A Review of Treatment Options |
title_fullStr | Atopic Dermatitis in Older Adults: A Review of Treatment Options |
title_full_unstemmed | Atopic Dermatitis in Older Adults: A Review of Treatment Options |
title_short | Atopic Dermatitis in Older Adults: A Review of Treatment Options |
title_sort | atopic dermatitis in older adults: a review of treatment options |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044141/ https://www.ncbi.nlm.nih.gov/pubmed/32086792 http://dx.doi.org/10.1007/s40266-020-00750-5 |
work_keys_str_mv | AT taneiryoji atopicdermatitisinolderadultsareviewoftreatmentoptions |